Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2022-12-14 19:15:05
Oslo, 14. December 2022. The Board of Directors of Lytix Biopharma AS (the
"Company") has resolved to grant 1,194,000 share options in the Company
("Options") under the Company's long term incentive program.
The following primary insiders of Lytix Biopharma AS have been granted and
allocated Options:
- Øystein Rekdal, CEO: 420,000 Options
- Baldur Sveinbjørnsson, CSO: 100,000 Options
- Gjest Breistein, CFO: 67,000 Options
- Gry Stensrud, CTO: 67,000 Options
The Options are granted without consideration and each Option will upon exercise
give the right to acquire one share in the Company. The exercise price of each
Option is NOK 8.50, which equals to the closing share price of the Company on
Euronext Growth Oslo, the day prior to grant of the Options.
The Options will vest gradually pursuant to specific vesting schedules:
- 13,000 Options will vest on the date of grant and 37,000 Options will vest
with 1/36 on the last day of the 36 following months.
- 40,000] Options will vest on 31 January 2023 and 120,000 Options will vest
with 1/36 on the last day of the 36 following months.
- 246,500 Options will vest 12 months after the date of grant, while the
remaining 737,500 Options will vest with 1/36 on the last day of the 36
following months.
Vesting of Options is subject to the Option holder being qualified to be part of
the Company's long term incentive program at each vesting date.
All Options will expire and lapse if not exercised within five years from the
date of grant.
Please refer to the forms appended hereto for the disclosure of Option grants to
primary insiders of the Company.
For further information, please contact:
Gjest Breistein, CFO
Email: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of Communication and Investor Relations
Email: ole.peter.nordby@lytixbiopharma.com
This announcement is made pursuant to section 5-12 of the Norwegian Securities
Trading Act and article 19 of the Market Abuse Regulation.